Analysis of Vaccination Rates of 23-Valent Pneumococcal Polysaccharide Vaccine in Hospitalized Patients with Diabetes

被引：0
|
作者：
Seagroves, Amy
Reh, Christina S.
Bischoff, Nathaniel
Nally, Laura M.
Singh, Jasjit
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1409-P
引用
收藏
页码：A377 / A378
页数：2
相关论文
共 50 条
  • [41] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Jansen, Kathrin U.
    Jayawardene, Deepthi
    Devlin, Carmel
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3577 - 3584
  • [42] Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
    Russell, F. M.
    Carapetis, J. R.
    Satzke, C.
    Tikoduadua, L.
    Waqatakirewa, L.
    Chandra, R.
    Seduadua, A.
    Oftadeh, S.
    Cheung, Y. B.
    Gilbert, G. L.
    Mulholland, E. K.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (12) : 1970 - 1976
  • [43] Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia
    Lindstrom, Vesa
    Aittoniemi, Janne
    Salmenniemi, Urpu
    Kayhty, Helena
    Huhtala, Heini
    Sinisalo, Marjatta
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (12) : 2910 - 2913
  • [44] Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly
    Won, Heehyun
    Kim, Jeong Ah
    Jeong, Na-Young
    Choi, Nam-Kyong
    VACCINE, 2024, 42 (13) : 3190 - 3196
  • [45] Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly
    Won, Heehyun
    Kim, Jeong Ah
    Jeong, Na-Young
    Choi, Nam-Kyong
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 24 - 25
  • [46] A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
    Ngamprasertchai, Thundon
    Kositamongkol, Chayanis
    Lawpoolsri, Saranath
    Rattanaumpawan, Pinyo
    Luvira, Viravarn
    Chongtrakool, Piriyaporn
    Kaewkungwal, Jaranit
    Chokephaibulkit, Kulkanya
    Phisalprapa, Pochamana
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [47] Does 23-Valent Pneumococcal Polysaccharide Vaccination Decrease All-Cause Mortality?
    Rezahosseini, Omid
    Eiberg, Mads Frederik
    Weinberger, Daniel M.
    Harboe, Zitta Barrella
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (11):
  • [48] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
    Shiramoto, Masanari
    Hanada, Ryuzo
    Juergens, Christine
    Shoji, Yasuko
    Yoshida, Mizuki
    Ballan, Barry
    Cooper, David
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
  • [49] Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia
    Van Buynder, Paul
    Cripps, Allan W.
    VACCINE, 2019, 37 (24) : 3141 - 3141
  • [50] Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia
    Chen, C.
    Beutels, P.
    Wood, J.
    Menzies, R.
    Maclntyre, C. R.
    McIntyre, P.
    Newall, A. T.
    VACCINE, 2018, 36 (42) : 6307 - 6313
12345